Exane Derivatives Checkpoint Therapeutics, Inc. Transaction History

Exane Derivatives

$157 Million
Q2 2022

A detailed history of Exane Derivatives transactions in Checkpoint Therapeutics, Inc. stock. As of the latest transaction made, Exane Derivatives holds 1,611 shares of CKPT stock, worth $5,735. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,611

Previous 28,853 94.42%

Holding current value

$5,735

Previous $51,000 98.04%

% of portfolio

0.0%

Previous 0.02%

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 12, 2022	SELL	$0.97 - $1.77 $26,424 - $48,218	-27,242 Reduced 94.42%	1,611 $1,000
Q1 2022 Apr 22, 2022	SELL	$1.53 - $3.25 $3,685 - $7,829	-2,409 Reduced 7.71%	28,853 $51,000
Q4 2021 Jan 28, 2022	SELL	$2.68 - $4.46 $45,474 - $75,677	-16,968 Reduced 35.18%	31,262 $97,000
Q3 2021 Oct 26, 2021	BUY	$2.5 - $3.53 $120,575 - $170,251	48,230 New	48,230 $159,000

Others Institutions Holding CKPT

# of Institutions

Shares Held

1.91M

Call Options Held

Put Options Held

View Full List

About Checkpoint Therapeutics, Inc.

Ticker CKPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 85,497,000
Market Cap $304M
Description
Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to...

More about CKPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Exane Derivatives, based on Form 13F filings with the SEC.

News

Stay updated on Exane Derivatives with notifications on news.

Account

Exane Derivatives Checkpoint Therapeutics, Inc. Transaction History